Takeda inks two development pacts | Chemical & Engineering News
Volume 94 Issue 28 | p. 14 | Concentrates
Issue Date: July 11, 2016

Takeda inks two development pacts

Department: Business
Keywords: pharmaceuticals, Crohn’s Disease, stem cell, licensing

Takeda Pharmaceuticals will work with Belgium’s TiGenix to develop the latter’s stem cell therapy for Crohn’s disease outside the U.S. TiGenix will receive an up-front payment of $28 million, as well as potential milestone and royalty payments. Takeda also will invest $11 million in the Belgian firm. Separately, Takeda is forming a partnership with Altos Therapeutics to develop Altos’s ATC-1906, an oral dopamine D2/D3 receptor antagonist, for the treatment of gastroparesis. The agreement gives Takeda an exclusive option to acquire Altos through Phase I development of the drug.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment